Lifordi Immunotherapeutics Unveils Promising Preclinical Data for LFD-200 at EULAR 2025
TL;DR
Lifordi Immunotherapeutics' LFD-200 offers a competitive edge by targeting immune cells directly, reducing systemic toxicity and broadening steroid use in autoimmune treatments.
LFD-200 utilizes an Anti-VISTA monoclonal antibody to deliver glucocorticoids directly to immune cells, ensuring rapid uptake and sustained efficacy without off-target toxicity.
LFD-200's targeted therapy promises a safer, more effective treatment for autoimmune diseases, improving patient quality of life and reducing systemic side effects.
Discover how Lifordi's LFD-200 revolutionizes autoimmune treatment by delivering drugs directly to immune cells, offering hope for diseases like arthritis and asthma.
Found this article helpful?
Share it with your network and spread the knowledge!
Lifordi Immunotherapeutics, Inc. has taken a significant step forward in the treatment of autoimmune and inflammatory diseases with the presentation of preclinical data on LFD-200 at the European Alliance of Associations for Rheumatology (EULAR) meeting in Barcelona. The data highlights LFD-200's ability to deliver a glucocorticoid payload directly to immune cells, achieving targeted efficacy while avoiding the systemic toxicity associated with traditional steroid treatments.
The studies, conducted in mice and non-human primates, demonstrated that LFD-200 ensures rapid uptake by target tissues and sustains glucocorticoid exposure in immune tissues for more than seven days. This targeted approach significantly reduces the risk of off-target toxicity, a common limitation in current treatments. Notably, LFD-200 showed no evidence of systemic glucocorticoid toxicity after prolonged dosing, a critical advancement in the field.
Dr. Matthew W. McClure, Chief Medical Officer of Lifordi, presented these findings, emphasizing the potential of LFD-200 to revolutionize the treatment of autoimmune and inflammatory conditions. The drug's efficacy was comparable to dexamethasone in preventing colitis development, with disease control observed for up to three weeks post-dose. Similar success was noted in other disease models, including diabetes, arthritis, asthma, and xeno-graft vs. host disease.
The implications of these findings are vast, offering hope for patients suffering from a range of autoimmune and inflammatory diseases. By targeting the immune system directly and sparing non-immune tissues, LFD-200 could pave the way for safer, more effective treatments across rheumatology, gastroenterology, pulmonology, and dermatology. Lifordi Immunotherapeutics is now preparing for a Phase 1 clinical study, with initial data expected by the end of 2025.
Curated from Reportable
